Higher lymphocyte count associated with larger hippocampal volume and fewer depressive symptoms in drug-na ïve first-episode psychosis

dc.contributor.authorToll Privat, Alba
dc.contributor.authorBlanco Hinojo, Laura
dc.contributor.authorBergé, Daniel
dc.contributor.authorMartín-Subero, Marta
dc.contributor.authorCasanovas, Francesc
dc.contributor.authorEl Abidi El Ghazouani, Khadija
dc.contributor.authorPérez Solà, Victor
dc.contributor.authorMané, Anna
dc.date.accessioned2026-01-19T14:04:35Z
dc.date.available2026-01-19T14:04:35Z
dc.date.issued2023-04-01
dc.date.updated2026-01-19T14:04:35Z
dc.description.abstractCirculating white blood cells (leucocytes), which form the peripheral immune system, are crucial in inflammatory processes but their role in brain structural change in schizophrenia has been scarcely studied. With this study we want to determine how and which type of white blood cells are associated with hippocampal volume (as a key structure in schi- zophrenia etiopathology) in first episode psychosis (FEP) patients. Moreover, to determine the association between white blood cells and clinical symptomatology, including positive and negative symptoms, cognition and depression. For this purpose fifty drug-naïve FEP were included in this study. All patients underwent an assessment at baseline and at 1 year follow-up, including sociodemographic and clinical variables (substance use, DUP, PANSS, GAF and CDSS). Fasting blood samples were obtained before administering any medication at baseline. Structural T1 MRI was performed at baseline and brain volumes were quantified. In the present study, higher lymphocyte count was associated with larger right hippocampal volume at baseline in FEP drug-naive patients. Higher lymphocyte count was associated with lower depressive symptomatology measured with CDSS and Marder depressive factor from PANSS at baseline and 1-year follow -up. These results suggest that lymphocytes may have a protective effect in hippocampal volume at baseli- ne in antipsychotic naïve FEP and also, are associated with a better depressive course over follow up. These results open the door to identify new biomarkers and therapeutic targets for patients with schizophrenia.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec732297
dc.identifier.issn0924-977X
dc.identifier.pmid36709614
dc.identifier.urihttps://hdl.handle.net/2445/225712
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.euroneuro.2023.01.002
dc.relation.ispartofEuropean Neuropsychopharmacology, 2023, vol. 69, p. 47-55
dc.relation.urihttps://doi.org/10.1016/j.euroneuro.2023.01.002
dc.rightscc-by-nc-nd (c) Toll Privat, Alba et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.classificationDepressió psíquica
dc.subject.classificationHipocamp (Cervell)
dc.subject.classificationPsicosi
dc.subject.otherMental depression
dc.subject.otherHippocampus (Brain)
dc.subject.otherPsychoses
dc.titleHigher lymphocyte count associated with larger hippocampal volume and fewer depressive symptoms in drug-na ïve first-episode psychosis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
259283.pdf
Mida:
874.32 KB
Format:
Adobe Portable Document Format